A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT2A Receptor Density in the Pig Brain
Open accessPublished version of a preprint
The DOI matches its Crossref record; 45 of the 48 references it cites were found in a registry or an index.
Abstract
A single dose of psilocybin, a psychedelic and serotonin 2A receptor (5-HT2AR) agonist, may be associated with antidepressant effects. The mechanism behind its antidepressive action is unknown but could be linked to increased synaptogenesis and down-regulation of cerebral 5-HT2AR. Here, we investigate if a single psychedelic dose of psilocybin changes synaptic vesicle protein 2A (SV2A) and 5-HT2AR density in the pig brain. Twenty-four awake pigs received either 0.08 mg/kg psilocybin or saline intravenously. Twelve pigs (n = 6/intervention) were euthanized one day post-injection, while the remaining twelve pigs were euthanized seven days post-injection (n = 6/intervention). We performed autoradiography on hippocampus and prefrontal cortex (PFC) sections with [3H]UCB-J (SV2A), [3H]MDL100907 (5-HT2AR antagonist) and [3H]Cimbi-36 (5-HT2AR agonist). One day post psilocybin injection, we observed 4.42% higher hippocampal SV2A density and lowered hippocampal and PFC 5-HT2AR density (−15.21% to −50.19%). These differences were statistically significant in the hippocampus for all radioligands and in the PFC for [3H]Cimbi-36 only. Seven days post-intervention, there was still significantly higher SV2A density in the hippocampus (+9.24%) and the PFC (+6.10%), whereas there were no longer any differences in 5-HT2AR density. Our findings suggest that psilocybin causes increased persistent synaptogenesis and an acute decrease in 5-HT2AR density, which may play a role in psilocybin’s antidepressive effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure A1 Saturation assay of [3H]UCB-J (a), [3H]MDL100907 (b) and [3H]Cimbi-36 (c) in the grey matter of the pig brain.](https://figures.cochat.ai/paper-figures/38d25f421ca64d38a1c3569974548753/a-single-dose-of-psilocybin-increases-synaptic-density-and-decreases-5-ht2a-figure-1.jpg)
![Figure 1 Group-wise comparisons of synaptic vesicle protein 2A (SV2A) density (mean ± SD) in the hippocampus (a) and prefrontal cortex (PFC) (b) as measured with [3H]UCB-J autoradiography.](https://figures.cochat.ai/paper-figures/6f3973e6df5d483a8417e5831679ac65/a-single-dose-of-psilocybin-increases-synaptic-density-and-decreases-5-ht2a-figure-1.jpg)
![Figure 2 Group-wise comparison of 5-HT2AR density (mean ± SD) as measured with [3H]MDL100907 and [3H]Cimbi-36 in the hippocampus (a,c) and PFC (b,d) using autoradiography.](https://figures.cochat.ai/paper-figures/aa078f12462a4e58b83778f85f9b47a1/a-single-dose-of-psilocybin-increases-synaptic-density-and-decreases-5-ht2a-figure-2.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Psilocybin has also been shown to increase the density of SV2A in vivo as measured by PET imaging (155).”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [155]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“new imaging tools have the potential to identify biomarkers of psychoplastogen efficacy”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [155]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Using [3H]UCB-J in vitro autoradiography, we recently showed that a single administration of the 5-HT2A receptor agonist psilocybin was associated with higher hippocampal SV2A levels in awake pigs 24 h after administration [52].”
From Effects of escitalopram on synaptic density in the healthy human brain: a randomized controlled trial (2023) · cites this paper as [52]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIH Image to ImageJ: 25 years of image analysis
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012) · Nature Methods · doi:10.1038/nmeth.2089 · Cited by 64,638 · cited 2×
“Calibration, quantification and data evaluation was done using ImageJ software (NIH Image, Bethesda, MD, USA) [45].”
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 1×
“We investigate brain effects one day after psilocybin administration because the days following a psychedelic experience may provide a therapeutic window to treat mood disorders [6,7].”
InfluentialRoss, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · cited 2×
“A follow-up seven days after a psilocybin intervention is done because this is when depressive scores have been reported to be the lowest [6].”
InfluentialEffects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207 · cited 2×
“The increase in synaptic marker SV2A may result from the stimulation of the 5-HT2AR, TrkB and mTOR signalling pathways [10].”
Pompeiano, M., Palacios, J. M., & Mengod, G. (1994) · Molecular Brain Research · doi:10.1016/0169-328x(94)90223-2 · Cited by 881 · cited 1×
“More caution should be exerted when comparing the radioligands in hippocampus because the hippocampus has high levels of 5-HT2CR, with a density similar to 5-HT2AR [34,35] and [3H]Cimbi-36 also has affinity to 5-HT2CR [36,37].”
Decreased expression of synapse-related genes and loss of synapses in major depressive disorder
Kang, H. J., Voleti, B., Hajszan, T., Rajkowska, G., Stockmeier, C. A., Licznerski, P., Lepack, A., Majik, M. S., Jeong, L. S., Banasr, M., et al. (2012) · Nature Medicine · doi:10.1038/nm.2886 · Cited by 808 · cited 1×
“Both post-mortem human brain [14,15] and in vivo[16] studies in depressed individuals have shown a loss of synapses through the down-regulation of synaptic proteins and genes.”
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Vollenweider, F. X., & Kometer, M. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2884 · Cited by 723
Cited by
Items 201–218 of 218
de Oliveira, E. G. (2025) · Cross Connect (Southern Cross University) · doi:10.25918/thesis.558
Meshkat, S., Jha, M. K., & Bhat, V. (2026) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20250043
Wilde, A. (2026) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Severance, T. (2026) · Digital Commons at National Lewis University (National Lewis University)
Effects of psilocybin on sleep quality and brain microstructure in chronic cluster headache
Brendstrup‐Brix, K., Ozenne, B., Fisher, P. M., Stenbæk, D. S., Petersen, A. S., Armand, S., McCulloch, D. E.-W., Marstrand-Joergensen, M. R., Larsen, S. M. U., Johansen, A., et al. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261449380
Self-citationAhmadian-Moghadam, S., Roshan‐Milani, S., & Saboory, E. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-04151-x
“This suggests psilocybin induces lasting synaptogenesis alongside a transient reduction in 5-HT2AR density [114].”
Jalalian-Javadpour, M., Yekta, B. G., Reyhani, N., Hajizamani, S., Azizi, A., Azad, N. K., Mohammadi, H., & Vaseghi, S. (2026) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2026.101098
Du, Y. J., Zhao, X., Yao, Y., Li, Y., Wang, G., & Zhang, L. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261453819
Olejníková, L., Kútna, V., Mazochová, K., Šíchová, K., Danda, H., Lhotková, E., Uttl, L., Brejtr, V., Syrová, K., Mazoch, V., et al. (2026) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2026.174231
Wawrzczak‐Bargieła, A., Jelonek-Kozioł, M., Kumorek, W., Bilecki, W., & Maćkowiak, M. (2026) · Psychopharmacology · doi:10.1007/s00213-026-07132-6
Mapping excitatory synaptic plasticity evoked by single-dose psilocybin in micePreprint
Li, Z., Weber, C., Sellitti, F., & Simmler, L. D. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.31.741703
Potential Role of Psychedelics in the Treatment of Depressive Disorder
Wang, S., & Bahk, W.-M. (2026) · Springer eBooks · doi:10.1007/978-981-92-1331-3_12
Kelly, C., Cooley, B. J., Zeng, L., Hurzeler, T. P., Manning, V., McNally, G. P., Watt, J., Haber, P., & Morley, K. C. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106911
Chytas, V., Tsimploulis, G., & Chytas, D. (2026) · Psychedelic Medicine · doi:10.1177/28314425261489067
Savini, M. J., King, K. M., Puppel, L. P., Al-Olimat, A. K., Molnar, N. M., Schneider, E. J., Straub, S. E., Parker, J., Gottron, C. J., Bach, A. M., et al. (2026) · Psychopharmacology · doi:10.1007/s00213-026-07188-4
Yngwe, H., Sigray, P. P., Andersson, M., Bolin, M., Beckman, M., Ekman, C. J., Tiger, M., & Lundberg, J. (2026) · medRxiv · doi:10.64898/2026.10.27.26366602 · Cited by 1
Sayalı, C., Weisman, E., & Barrett, F. S. (2026) · medRxiv · doi:10.64898/2026.10.27.26366630
Yngwe, H., Sigray, P. P., Andersson, M., Bolin, M., Beckman, M., Ekman, C. J., Tiger, M., & Lundberg, J. (2026) · medRxiv · doi:10.64898/2026.11.06.26367247
Metadata
- Authors
- Raval, N. R., Johansen, A., Donovan, L. L., Ros, N. F., Ozenne, B., Hansen, H. D., & Knudsen, G. M.
- Affiliations
- University of Copenhagen (DK)
- Copenhagen University Hospital (DK)
- Harvard University (US)
- Corresponding author
- Hansen, Hanne Demant
- Knudsen, Gitte Moos
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-01-15
- Volume
- 22
- Issue
- 2
- Pages
- 835
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7830000
- OpenAlex
- W3108222140
- Cited by
- 200
- References
- 48
- Citations by year
- 2026: 31 · 2025: 38 · 2024: 40 · 2023: 41 · 2022: 33 · 2021: 17
- FWCI
- 22.34
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Preprints.org (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, cc-by)
- Funders
- Horizon 2020 (813528)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- psilocybin, 5-HT2A receptor, synaptic density, synaptogenesis, SV2A, hippocampus, prefrontal cortex, antidepressant mechanism, psychedelics, pig brain, receptor down-regulation
- MeSH terms
- Animals, Antidepressive Agents, Autoradiography, Brain, Female, Hallucinogens, Hippocampus, Ligands, Psilocybin, Swine, Synapses, Prefrontal Cortex, Receptor, Serotonin, 5-HT2A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.